rhEPO in pediatric oncology


Recent improvement in survival of pediatric cancer patients is due to the results of combined management including surgery, chemotherapy (high-dose, adjuvant, long-term, etc.), and radiotherapy (fractionated, local therapy, plaque therapy, high dosage, etc). For many years, recombinant hematopoietic growth factors have been used to reduce the degree and duration of chemotherapy-induced myelosuppression, the main adverse effect of chemotherapy (Furman 1992; Trillet-Lenoir et al. 1993; Burdach et al. 1995; Riikonen et al. 1995; Mitchell et al. 1997; Rahiala et al. 1999).


Platelet Transfusion Pediatric Oncology None None Recombinant Human Erythropoietin Pediatric Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abels RI (1992) Recombinant human erythropoietin in the treatment of the anemia of cancer. Acta Haematol 87 (Suppl 1): 4–11PubMedCrossRefGoogle Scholar
  2. 2.
    Aledort LM, Mohandas K (1996) Transfusion requirements in patients with malignancy. Semin Hematol 33 (Suppl 1): 6–9PubMedGoogle Scholar
  3. 3.
    Albertazzi L, Baglioni T, Belloni M, Benedetti F, Benedetti G, Bini P, Bizzi B, Casi C et al (1995) Le cellule staminali emopoietiche: tecnologie — indicazioni — utilizzo. Maurizio Marangolo Milano, pp 180–183Google Scholar
  4. 4.
    Beck NM, Beck D (1995) Recombinant erythropoietin in acute chemotherapy induced anemia of children with cancer. Med Pediatr Oncol 25: 17–21PubMedCrossRefGoogle Scholar
  5. 5.
    Bolonaki I, Stiakaki E, Lydaki E, Dimitriou H, Kambourakis A, Kalmantis TH, Kalmanti M (1996) Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol 13: 111–121PubMedCrossRefGoogle Scholar
  6. 6.
    Burdach SEG, Müschenich M, Josephs W, Frisch J, Schultz G, Jürgens H, Göbel U (1995) Granulocyte-macrophage-colony-stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study. Cancer 76: 510–516PubMedCrossRefGoogle Scholar
  7. 7.
    Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 12: 1058–1062PubMedGoogle Scholar
  8. 8.
    Corazza F, Beguin Y, Bergmann P, André M, Ferster A, Devalck C, Fondu P, Buyse M, Sariban E (1998) Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood 92: 1793–1798PubMedGoogle Scholar
  9. 9.
    Csâki C, Ferencz T, Schuler D, Borsi JD (1998) Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours. Eur J Cancer 34: 364–367PubMedCrossRefGoogle Scholar
  10. 10.
    Ferencz T, Csaki CS, Koos R et al (1991) Transfusional requirements following chemotherapy in pediatric solid tumour. Erythropoiesis 5: 115–118Google Scholar
  11. 11.
    Funian WL, Crist WM (1992) Biology and clinical applications of hemopoietins in pediatric practice. Pediatrics 90: 716–728Google Scholar
  12. 12.
    Jamal R, Fadzillah G, Zulkifli SZ, Yasmin M (1998) Seroprevalence of hepatitis B, hepatitis C, CMV and HIV in multiply transfused thalassemia patients: results from a thalassemia day care center in Malaysia. Southeast Asian J Trop Med Public Health 29 (4): 792–4PubMedGoogle Scholar
  13. 13.
    Jelkmann W (1992) Erythropoietin: structure, control of production, and function. Physiol Rev 72: 449–489PubMedGoogle Scholar
  14. 14.
    Jimenez FP, Fuentes HM, Borbolla Busquet E (2000) Anti-HCV in patients transfused, in a health area attended by a family physician. Medical Office 19 de Abril. Acta Gastroenterol Latinoam 30 (2): 99–105PubMedGoogle Scholar
  15. 15.
    Kasper C, Terhaar A, Fossa A, Welt A, Seeber S, Nowrousian MR (1997) Recombinant human erythropoietin in the treatment of cancer related anemia. Eur J Haematol 58: 251–256PubMedCrossRefGoogle Scholar
  16. 16.
    Leòn P, Jimenéz M, Barona P, Sierrasesùmaga L (1998) Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol 30: 110–116PubMedCrossRefGoogle Scholar
  17. 17.
    Locatelli F, Zecca M, Pedrazzoli P et al (1994) Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 13: 403–410PubMedGoogle Scholar
  18. 18.
    MacMillan M, Freedman MH (1998) Recombinant human erythropoietin in children with cancer. J Pediatr Hematol Oncol 20 (3): 187–189PubMedCrossRefGoogle Scholar
  19. 19.
    Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322: 1689–1692PubMedCrossRefGoogle Scholar
  20. 20.
    Mitchell PLR, Morland B, Stevens MGC, Dick G, Easlea D, Meyer LC, Pinkerton CR (1997) Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 15: 1163–1170PubMedGoogle Scholar
  21. 21.
    Nowrousian MR, Kasper C, Oberhoff C, Essers U, Voigtmann R, Gallasch W, Quarder O (1996) Pathophysiology or cancer-related anemia. In: Smyth JF, Boogaerts MA, Ehmer BRM (eds) rhErythropoietin in cancer supportive treatment. Dekker, New York Basel Hong Kong, pp 13–34Google Scholar
  22. 22.
    Porter JC, Leahey A, Polise K, Bunin G, Manno C (1996) Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr 129: 656–660PubMedCrossRefGoogle Scholar
  23. 23.
    Rahiala J, Perkkio M, Riikonen P (1999) Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer. Med Pediatr Oncol 32: 326–330PubMedCrossRefGoogle Scholar
  24. 24.
    Riikonen P, Rahiala J, Salonvaara M, Perkkio M (1995) Prophylactic administration of Granulocyte Colony-Stimulating factor ( Filgrastim) after conventional chemotherapy in children with cancer. Stem Cells 13: 289–294PubMedCrossRefGoogle Scholar
  25. 25.
    Rosso R, Del Mastro L, Venturini M, Bersaglio M, Pasquetti W, Garrone O (1997) Uso dell’eritropoietina in oncologia. Tumori 83 (Suppl 2): S26 - S30PubMedGoogle Scholar
  26. 26.
    Tamary H, Danon YL (1996) Recombinant human erythropoietin in children with cancer. Pediatr Hematol Oncol 13: 305–308PubMedCrossRefGoogle Scholar
  27. 27.
    Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzmeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tornita D, Ewen C (1993) Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29: 319–324CrossRefGoogle Scholar
  28. 28.
    Varan A, Buyukpamukcu M, Kutluk T et al (1999) Recombinant Human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics 2: 16CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2002

Authors and Affiliations

  1. 1.Oncology Service, Pediatric DepartmentUniversity of Rome “La Sapienza”Italy

Personalised recommendations